If Paper Cuts Could Kill: The World Health Organization Launches its Antimicrobial Resistance Campaign

By Thanusha Pillay

May 21, 2024

Introduction:

In 1928, Alexander Fleming discovered penicillin, the first antibiotic. Since then, antimicrobials have completely shifted healthcare, saving countless lives that would have otherwise been lost to anything from the tiniest scrape to an otherwise safe childbirth. However, the rise of antimicrobial resistance (AMR) threatens this progress, rendering once-effective treatments ineffective. AMR presents a global crisis, impacting health, economies, and livelihoods worldwide – yet many people aren’t even aware this threat exists.

The Silent Threat of AMR:

The resistance of microbes – bacteria, viruses, fungi, and parasites – poses a grave challenge. When these microorganisms no longer respond to treatments, infections become difficult to treat or untreatable, elevating the risk of severe illness and mortality. The toll is staggering, with 1.3 million deaths directly attributed to AMR annually, and a further 5 million AMR-related deaths. AMR also threatens future livelihoods, with an estimated annual cost of US$3.4 trillion by 2030 and 28 million people becoming poverty-stricken by 2050.

Human Cost of AMR:

Beyond statistics lies real people and their families. AMR leads to limited treatment options, prolonged hospital stays, financial strain, and emotional turmoil. The impact is indiscriminate, affecting individuals regardless of health status, with even minor ailments posing life-threatening risks. Clinically vulnerable individuals such as those with cancer, diabetes, or HIV, risk facing a dangerous infection that their bodies have little chance of overcoming without an effective treatment.

A Global Menace:

AMR transcends borders, posing a dual threat to public health and food security. Straining healthcare systems, AMR undermines treatment efficacy, prolonging illnesses and inflating healthcare costs. Moreover, the spread of AMR through the food chain jeopardises both animal and human health, crippling agricultural economies worldwide.

Voices Against AMR:

In a bid to spur action, the WHO has launched their AMR Awareness Campaign and called upon 12 survivors and advocates to share their poignant experiences with AMR. This emphasises the urgent need for intervention to combat this silent adversary. Last year, the WHO also published a global research agenda for antimicrobial resistance in human health, prioritising evidence generation for 40 research topics that will inform policy by 2030.

Unity in the Face of Adversity:

Much like the response to COVID-19, addressing drug-resistant infections demands a united front. AMR respects no boundaries, necessitating collaborative efforts on a global scale. The battle against AMR is a collective responsibility, requiring coordinated action to safeguard public health, food security, and sustainable development goals.

Call to Action:

Join the fight against AMR. Together, we can preserve the efficacy of antimicrobial medicines, protect lives, and secure a healthier future for all. Raise awareness, advocate for responsible antimicrobial use, and support initiatives aimed at combating this pressing global threat.

Reference url

Recent Posts

EU Launches Joint Scientific Consultations to Enhance Health Technology Assessment

By João L. Carapinha

January 14, 2026

Launching Joint Scientific Consultations in 2026 The European Commission has initiated the first submission period for Joint Scientific Consultations under the EU Health Technology Assessment (HTA) Regulation. This marks the third su...
Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays

By HEOR Staff Writer

January 13, 2026

Portugal's Epidyolex spending has topped €3 million since 2021, fueling debates on access to this CBD-based epilepsy drug through the National Health Service (SNS). If you're wondering how this impacts patient care and healthcare costs, the answer lies in Infarmed's nearly four-year evaluation fo...
Empowering Leaders at the Global Pharma Executive Course: Navigating Industry Transformation
The fourth edition of the Global Pharma Executive Course runs from March to May 2026 at Portugal's Faculdade de Medicina da Universidade Católica Portuguesa and Hospital da Luz Lisboa. The course targets pharma industry leaders, as rapid changes driven by tech advances, therapeutic innovation, an...